Carter Todd Alfred 4
4 · Voyager Therapeutics, Inc. · Filed Sep 18, 2023
Insider Transaction Report
Form 4
Carter Todd Alfred
Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-09-15$8.16/sh−10,500$85,680→ 54,360 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-15−5,000→ 40,000 totalExercise: $2.85Exp: 2032-01-13→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2023-09-15$2.85/sh+5,000$14,250→ 64,860 total
Footnotes (2)
- [F1]The reported sale of 10,500 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.
- [F2]This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date of the option is the grant date, January 13, 2022. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.